A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc)
Sponsor: Ergomed
A PHASE2 clinical study on Systemic Sclerosis, this trial is completed. The trial is conducted by Ergomed and has accumulated 9 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 4 earlier versions
-
Feb 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Mar 2021 — Sep 2021 [monthly]
Recruiting PHASE2
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ergomed
- Gesynta Pharma AB
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bath, United Kingdom , Cambridge, United Kingdom , Dundee, United Kingdom , Gdansk, Poland , Ghent, Belgium , Krakow, Poland , Leeds, United Kingdom , Liverpool, United Kingdom , London, United Kingdom , Lublin, Poland and 2 more locations